NEW BATCH!

Ofatumumab

clinical grade

BATCH NUMBER: SKVX4

553,00 €

Therapeutic Ofatumumab monoclonal antibody from the original Kesimpta® commercial drug
Request For Quotation
Bulk deal
Quantity Discount
3 - 4 5%
5 - 7 10%
8 - 11 15%
12 + 25%
Bulk pricing will be applied to package:
  • Product with SKUs from the list: '08002375_SKVX4'

In stock

Product specifications:​

  • Quality Standard clinical-grade
  • Product Concentration 50 mg/mL
  • Volume per vial 20 µL
  • Quantity per vial 1 mg
  • Origin of the commercial drug DE
  • Batch Number SKVX4
  • Storage Temperature -80 °C
  • Original therapeutic expiry date: 2025.12

Our products are for research use only. The “therapeutic expiration date” implies expiry date for patient administration and is not applicable to the shelf life of the aliquot. Aliquot storage at -86°C ensures fully functional molecules even after the mentioned expiry date.

Product Information:

Evidentic offers repackaged finished pharmaceutical products (e.g RMP/RLD). We refer to the repackaged RMP/RLD products synonymously as drug aliquots or aRMP, or short: aliquots.

We offer batches of original drug aliquots in low-binding Eppendorf tubes for research use only. We provide license-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

As ‘raw material’ for the production of drug aliquots, Evidentic sources RMP from the European (EU) market. As a licensed pharmaceutical wholesaler, Evidentic is committed to Good Distribution Practice (GDP) compliance with respect to the procurement, storage and shipment of RMP.
Drug aliquots are manufactured by repackaging RMP in a qualified laboratory. The aliquotation process is performed under a quality and manufacturing agreement between Evidentic and the contract manufacturer. Repackaging of RMP includes the following steps: opening the secondary and primary RMP containers and transferring the specified volumes of RMP into an Eppendorf 0.5 ml low-binding (or similar) tube. If the RMP is a lyophilized powder and not a highly concentrated solution, reconstitute the RMP according to the original manufacturer’s instructions and then aliquot as a highly concentrated solution.
For identification purposes, drug aliquots are labeled with the date of aliquoting, the original lot number of the RMP, the original expiration date of the RMP, the name of the active ingredient (INN), and a unique identification code.
Immediately after aliquoting, drug aliquots are stored at either 2-8 °C or -86 °C for long-term storage. All drug aliquots stored at 2-8 °C are transferred to -86 °C at least two weeks before the expiration date of the original RLD/RMP is reached. Further quality or functional testing are not performed on the drug aliquots.  

Target

Class of molecule

Isotype

Host cells

Murine cell line (NS0)

Prepared from (Reference drug)​

Kesimpta®

Therapeutic Area

Therapeutic Indications

Mechanism of Action (MoA)

Ofatumumab is a fully human anti-CD20 monoclonal immunoglobulin G1 (IgG1) antibody. The CD20 molecule is a transmembrane phosphoprotein expressed on B lymphocytes from the pre-B to mature B lymphocyte stage. The CD20 molecule is also expressed on a small fraction of activated T cells. The binding of ofatumumab to CD20 induces lysis of CD20+ B cells primarily through complement-dependent cytotoxicity (CDC) and, to a lesser extent, through antibody-dependent cell-mediated cytotoxicity (ADCC). Ofatumumab has also been shown to induce cell lysis in both high and low CD20 expressing cells. CD20-expressing T cells are also depleted by ofatumumab.

Pharmacotherapeutic group​​

Selective immunosuppressants

List of Excipients​

L-arginine
Sodium acetate trihydrate
Sodium chloride
Polysorbate 80
Disodium edetate dihydrate
Hydrochloric acid (for pH adjustment)
Water for injections

Batch specific analytical data available

Evidentic’s analytical service includes a comprehensive array of methods to support the drug development process, including, for example, structure, aggregation, degree of isomerization and N-glycans identification of the active pharmaceutical ingredient (API).

Ofatumumab

BATCH NUMBER: SKVX4

Request an individual offer​

+ download a free sample​

1. Choose your(s) method(s) of interest
2. Provide your contact details
3. Send us your request and download a free sample report


Please provide your contact information


send us your inquiry and download a free sample file


  • Target research – Target identification, selection & validation
  • Planning and screening preparation
  • Lead generation – Screening preparation, hit generation, screening & lead selection
  • Lead optimization – Lead characterization, candidate selection
  • Preclinical development – PK/PD studies of candidate

More Reference Drugs as Aliquots

Filter our product list:
API
Antigen / Target
Therapeutic Areas
Therapeutic Indications
Classes of molecule​s
Isotypes
Expiry Date
CoA
Filters Sort results
Reset Apply
No results found. Clear filters and try again?

VIEW MORE NEW BATCHES!

Not looking for Ofatumumab SKVX4?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Evidentic GmbH
Am Mühlenberg 10

14476 Potsdam | Germany

+49 (0) 30 959 99 8831
info@evidentic.com

Cookie Preferences

Linkedin Youtube Facebook Twitter Instagram

Thank you for your interest in our services.

We will respond to you within one working day. You can now download your sample report.